Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients’ quality of life

- Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%)

- About two-thirds of patients reported fatigue as the most severe symptom at diagnosis and survey completion, underscoring the effect of ITP on day-to-day quality of life

- Interim results of the ITP World Impact Survey (I-WiSh) one of the largest surveys ever conducted in ITP, were presented at EHA

Basel, June 15, 2018 – Many patients with the rare blood disorder immune thrombocytopenia (ITP) find the disease has a negative impact on their everyday quality of life, according to interim results of a Novartis survey, called I-WiSh, presented today at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden (Abstract #PF654).

I-WiSh, a collaboration among global ITP experts, patient groups and Novartis, aims to uncover the impact of the disease on daily life, and patients’ perceptions toward treatment and management of their condition.

Interim survey results from more than 1,300 ITP patients revealed that they have concerns about the impact of ITP on their quality of life. Results showed that more than one-third (36%) of patients said that having ITP had a high impact on their emotional well-being while 28% of patients had disease symptoms that caused them to miss work. About two-thirds of patients reported that fatigue was their most severe symptom at diagnosis (71%) and at survey completion (64%).

“Severe fatigue, in particular, was reported by many patients as the most difficult to manage symptom of ITP,” said Nichola Cooper, MD, clinical senior lecturer, Hammersmith Hospital, Imperial College London, London, United Kingdom, and Chair of the I-WiSh Steering Committee. “This is an important message for healthcare providers treating patients with this rare disease; ITP is about more than bruising and risk of bleeding.”

The I-WiSh Steering Committee developed the ITP Life Quality Index (ILQI), a ten-question tool designed to help quantify and monitor the quality of life impact of ITP on patients. The ILQI was validated in qualitative analyses prior to being unveiled in the I-WiSh survey and will allow clinicians to better monitor symptoms beyond bleeding and to rely on more than platelet counts when treating ITP patients.

“Some patients only realize their fatigue has become such an issue in their daily lives after it is corrected by treatment,” said Dr. Cooper. “The ILQI tool will help measure this correction more
accurately and could also play a crucial role in monitoring disease impact on quality of life beyond just relying on the platelet count alone."

Overall, the two main treatment goals reported by patients were achieving healthy blood counts (79%) and increasing their energy levels (55%).

“These initial data from the I-WISH survey reveal how a rare blood disease like ITP can significantly affect a patient’s ability to live and function in their day-to-day life,” said Samit Hirawat, MD, Head, Novartis Oncology Global Drug Development. “We believe these results demonstrate that, even beyond medicine, ITP patients are seeking compassion, support and understanding from family, friends so they can strive to live the best lives they can. These are important insights, and we will look to build them into the programs and services we develop to better support this community."

To raise awareness about ITP, Novartis has launched the #ITP3Wishes social media campaign to give voice to the hopes and dreams of patients and those who support them. The campaign encourages people to use their social media channels to share three ITP-related wishes with the #ITP3Wishes hashtag to inspire others and let their ITP voice be heard.

**About the ITP World Impact Survey (I-WISH)**
The international I-WISH survey is a cross-sectional survey of 1,400 patients with ITP and 480 healthcare providers who treat the condition from 14 countries (Canada, China, Colombia, Egypt, France, Germany, Italy, India, Japan, Norway, Spain, Turkey, United Kingdom and United States). The interim results were from more than 1,300 patients in 13 countries who completed an online questionnaire beginning in January 2018 to measure ITP-related symptoms and the impact of the condition on daily life, and patients’ perceptions toward treatment and management of their condition. Additional survey results will be presented later this year.

**About the ITP Life Quality Index (ILQI)**
The ITP Life Quality Index (ILQI) was originally developed by clinical experts and based on patient interviews that were conducted to provide evidence to confirm content validity, specifically regarding the relevance of concepts. A literature search was performed prior to the interviews to ensure the ILQI captured relevant concepts.

Fifteen semi-structured patient interviews were conducted with UK patients with ITP recruited via the UK ITP Support Association. Patients were asked open-ended questions to elicit spontaneous discussion of their experience, followed by questions that probed the concepts of interest. The interviews also involved cognitive debriefing of the ILQI using ‘think-aloud’ methods to assess understanding and relevance of items, instructions and response options. Verbatim transcripts were analyzed using thematic analysis techniques.

Patients were 67% female, had a mean age of 51.3 (SD=17.4, range 23-73) and a range of education levels. Qualitative analysis identified a variety of impacts associated with ITP, including fatigue (93%), emotional impacts (e.g., anxiety [80%]), impacts on daily living such as lack of ability to partake in sport [100%], impacts on work (e.g., absenteeism [40%]), financial impacts (e.g., working hours [40%]) and social impacts (e.g., relationship with family [60%]).

**About Immune Thrombocytopenia (ITP)**
Immune thrombocytopenia (ITP) is a rare and potentially serious blood disorder that is characterized by increased destruction and impaired production of platelets, which are blood cells that allow the blood to clot properly. People who have ITP often have purple bruises or tiny red or purple dots on the skin. They also display symptoms such as nosebleeds, bleeding from the gums during dental work, or other bleeding that is hard to stop.
potential for drops in platelet counts may also cause emotional distress and may result in a hindered ability to do work or embarrassment due to visible symptoms.

Immune thrombocytopenia is classified by duration from diagnosis into: newly diagnosed (0-3 months), persistent (3-12 months duration) and chronic (>12 months duration). Chronic ITP is more likely to occur in adults, and women are affected more often than men.

The goal of treatment in ITP is to maintain a safe platelet count that reduces the risk of bleeding. Treatment is determined by platelet levels and the severity of the symptoms. In most cases, drugs that alter the immune system's attack on the platelets are prescribed to help manage bleeding in adults.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 124,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com


# # #

Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com

Eric Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
eric.althoff@novartis.com

Michael Billings
Benign Hematology Communications
+1 862 778 8656 (direct)
+1 201 400 1854 (mobile)
michael.billings@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

Central
Samir Shah +41 61 324 7944
Pierre-Michel Bringer +41 61 324 1065
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188

North America
Richard Pulik +1 212 830 2448
Cory Twining +1 212 830 2417